Short term heart rate variability is preserved in Parkinson's disease under atomoxetine

This study demonstrates that a single dose of atomoxetine preserves short-term heart rate variability in Parkinson's disease patients, supporting its cardiovascular safety and viability as a treatment for neuropsychiatric symptoms.

The Gist

The Big Picture: A Safety Check for a "Brain Booster"

Imagine the brain of a person with Parkinson's disease as a house where the lights are flickering, and the electrical wiring is getting a bit frayed. One specific part of the wiring, called the Locus Coeruleus (let's call it the "Blue Switch"), is often damaged early on. This switch controls not just mood and focus, but also how the heart beats.

Doctors have found a drug called Atomoxetine (usually used for ADHD) that acts like a "dimmer switch" for the Blue Switch. It helps brighten the lights in the brain, potentially improving memory and mood in Parkinson's patients.

The Big Question: Since this drug turns up the volume on the brain's electrical system, could it accidentally blow a fuse in the heart? People with Parkinson's already have "flickering" heart rhythms, so adding a drug that boosts the nervous system feels risky.

The Study's Mission: This research team wanted to see if giving a single dose of Atomoxetine to Parkinson's patients would mess up their heart rhythm (specifically, something called Heart Rate Variability or HRV).

---

The Experiment: The "Heartbeat Dance"

To understand the results, we first need to understand Heart Rate Variability (HRV).

• The Metaphor: Imagine your heart is a dancer.
  • A bad dancer (low HRV) moves like a robot: beat, beat, beat, beat. It's too rigid and predictable. This is common in Parkinson's.
  • A good dancer (high HRV) moves with jazz: beat... pause... quick beat... slow beat. It adapts to the music and the environment. This flexibility is a sign of a healthy heart.

The researchers wanted to see if Atomoxetine would make the Parkinson's dancers stumble or if they could keep dancing safely.

How they did it:

1. The Cast: They recruited 15 Parkinson's patients and 22 healthy people (the control group).
2. The Setup: The patients came in for three visits.
   • Visit 1: Scans and baseline tests.
   • Visit 2 & 3: A "crossover" test. On one day, they took a placebo (a sugar pill). On another day, they took 40mg of Atomoxetine. Neither the patients nor the doctors knew which was which until the end.
3. The Measurement: While sitting quietly, they hooked the patients up to an ECG (heart monitor) for 10 minutes to watch the "dance" of their heartbeats.
4. The Brain Scan: They also used a super-powerful 7-Tesla MRI (like a high-definition camera for the brain) to take a picture of the "Blue Switch" (Locus Coeruleus) to see how much damage it had.

---

The Results: Good News for the Heart

1. The "Disease Effect" (Parkinson's vs. Healthy People)

First, they compared the Parkinson's patients (on the sugar pill) to the healthy people.

• The Finding: As expected, the Parkinson's patients were indeed dancing like robots. Their heart rhythms were less flexible (lower HRV) than the healthy group.
• The Connection: They found a direct link between the "Blue Switch" and the dance. The more damaged the Blue Switch was in the brain, the more robotic the heart dance became. It's like a broken remote control making the TV screen flicker.

2. The "Drug Effect" (Atomoxetine vs. Placebo)

This was the main event. Did the drug change the dance?

• The Finding: No. When the patients took Atomoxetine, their heart rhythm did not change. It stayed exactly the same as when they took the sugar pill.
• The Analogy: Imagine you put a new, powerful battery in a robot. You might expect the robot to start moving faster or shaking. But in this case, the robot kept dancing at the exact same steady, slightly-robotic pace. The drug helped the brain without disturbing the heart.

3. The "Safety Profile"

They also checked blood pressure and pulse.

• The Finding: The drug caused a tiny, harmless bump in blood pressure when lying down, but nothing dangerous. It didn't make the heart race or skip a beat.

---

Why This Matters

Think of this study as a safety inspection for a new car engine.

• The Problem: Parkinson's patients need a new engine (noradrenergic drugs) to fix their brain fog and mood issues.
• The Fear: Everyone was worried that this new engine might overheat the car's transmission (the heart).
• The Verdict: The inspection passed. The engine runs smoothly, and the transmission is safe.

The Takeaway:
This study gives doctors and patients the green light to use Atomoxetine for treating the non-motor symptoms of Parkinson's (like depression, anxiety, and brain fog) without worrying that it will cause heart problems. It suggests that we can "tune" the brain's chemistry to help the mind, without breaking the heart.

Summary in One Sentence

Even though Parkinson's disease makes the heart's rhythm less flexible, a single dose of the drug Atomoxetine does not make it worse, proving it is a safe option for treating the brain symptoms of the disease.

Technical Summary

1. Problem Statement

Parkinson's disease (PD) is characterized by early pathology in the noradrenergic locus coeruleus (LC), which contributes to both motor/non-motor symptoms and autonomic dysfunction. Repurposed noradrenergic drugs, specifically the noradrenaline reuptake inhibitor atomoxetine, have shown promise in improving cognitive and psychiatric symptoms in PD. However, a critical safety concern remains: PD patients already suffer from cardiac sympathetic denervation and autonomic dysfunction. There is a lack of documented evidence regarding the acute cardiovascular effects of atomoxetine in this specific population. The study aims to determine if a single dose of atomoxetine alters Heart Rate Variability (HRV)—a key metric of autonomic cardiac regulation—in people with PD, and to investigate the anatomical basis of HRV deficits in PD using high-field MRI.

2. Methodology

Study Design & Participants:

• Design: A randomized, double-blind, placebo-controlled crossover study for the PD group, alongside a cross-sectional comparison with healthy controls.
• Participants:
  • PD Group: $n=15$ (final analyzed sample) with idiopathic PD (Hoehn & Yahr 1.5–3), no dementia.
  • Control Group: $n=22$ age-, sex-, and education-matched healthy controls.
  • Note: Initial recruitment was higher (19 PD, 26 controls), but 4 PD and 4 controls were excluded due to ECG signal quality issues (arrhythmias/noise).
• Intervention: PD participants received a single 40 mg oral dose of atomoxetine or placebo in two sessions separated by $\ge$ 6 days. Blood plasma levels were confirmed at 2 hours post-dose (peak concentration).

Data Acquisition:

• ECG: 10-minute resting recordings (sitting upright) at 1000 Hz sampling rate.
• MRI: 7T ultra-high field MRI with a neuromelanin-sensitive 3D magnetization transfer weighted sequence to image the locus coeruleus. Integrity was quantified as a Contrast-to-Noise Ratio (CNR).
• Physiological Monitoring: Blood pressure and pulse rate were monitored at arrival, 2 hours post-dose, and session completion.

HRV Metrics:
Metrics were extracted using the PhysioNet Cardiovascular Signal Toolbox in three domains:

• Time-domain: SDNN, RMSSD, Acceleration Capacity (AC), Deceleration Capacity (DC).
• Frequency-domain: vLF, LF, HF power, and LF:HF ratio.
• Non-linear: SD1, SD2, SD1:SD2 ratio, Sample Entropy.

Statistical Analysis:

• Approach: Bayesian estimation of linear mixed-effects models was used (via the brms package in R).
• Rationale: Chosen for small sample sizes to incorporate "weakly informative" priors and provide full posterior distributions for uncertainty quantification.
• Inference: The Region of Practical Equivalence (ROPE) was defined as $\pm 0.1$ times the empirical standard deviation of the control group.
  • If the 95% Credible Interval (CI) falls entirely within the ROPE: Evidence for the null hypothesis (no difference).
  • If the 95% CI falls entirely outside the ROPE: Strong evidence for a difference.
• Correlations: Bayesian linear correlation tests were used to link caudal LC integrity (CNR) with altered HRV metrics.

3. Key Contributions

1. Safety Profile: Provides the first rigorous, high-resolution assessment of acute atomoxetine effects on cardiac autonomic function in PD using comprehensive HRV metrics.
2. Anatomical Correlate: Links specific HRV deficits in PD to the structural integrity of the caudal locus coeruleus using 7T neuromelanin-sensitive MRI.
3. Methodological Rigor: Demonstrates the utility of Bayesian inference with ROPE analysis in small-sample clinical trials to distinguish between "no effect" and "insufficient power."

4. Results

A. Drug Effect (Atomoxetine vs. Placebo in PD):

• Primary Finding: There was no significant change in short-term resting HRV following atomoxetine administration compared to placebo.
• Statistical Evidence: For all metrics (Time, Frequency, and Non-linear domains), the posterior means and 95% CIs fell within the ROPE.
  • Examples: SDNN (effect size = -0.12), RMSSD (effect size = 0.03), vLF, and SD2 all showed credible intervals overlapping with the null effect.
• Vitals: No significant changes in pulse rate or sitting blood pressure. A small, non-clinical elevation in supine diastolic blood pressure was noted but deemed not clinically significant.

B. Disease Effect (PD on Placebo vs. Healthy Controls):

• Primary Finding: PD patients exhibited significantly reduced HRV compared to controls across multiple domains.
• Significant Differences (Outside ROPE):
  • Time-domain: Reduced SDNN, reduced Acceleration Capacity, and reduced Deceleration Capacity.
  • Frequency-domain: Reduced vLF power.
  • Non-linear: Reduced SD2 (indicating reduced complexity/variability).
• Non-Significant Differences: RMSSD, LF, HF, LF:HF ratio, SD1, and Sample Entropy showed overlapping CIs with controls.

C. Locus Coeruleus Integrity Correlations:

• In the PD group, caudal LC integrity (CNR) was positively correlated with specific HRV metrics that were altered in the disease:
  • vLF power: Moderate positive correlation ($R_{median} = 0.38$, $BF = 2.65$).
  • SD2: Moderate positive correlation ($R_{median} = 0.41$, $BF = 3.08$).
• No significant correlations were found between LC integrity and SDNN, AC, or DC.

5. Significance and Conclusion

• Clinical Safety: The study concludes that a 40 mg dose of atomoxetine is cardiovascularly safe for people with Parkinson's disease in the short term. It does not exacerbate the existing autonomic dysfunction (reduced HRV) characteristic of PD.
• Therapeutic Implication: These findings support the repurposing of atomoxetine for treating cognitive and psychiatric symptoms in PD and related disorders (e.g., mild cognitive impairment, Alzheimer's), as it can modulate the noradrenergic system without compromising cardiac regulation.
• Pathophysiological Insight: The correlation between caudal LC integrity and specific HRV metrics (vLF and SD2) reinforces the role of the locus coeruleus in central cardiac control. It suggests that neuromelanin-sensitive MRI could serve as a biomarker to identify patients with noradrenergic deficits who might benefit from noradrenergic therapies.
• Future Directions: The authors recommend replication in larger cohorts with longer ECG recordings and chronic dosing to confirm long-term safety.

Limitations: Small sample size (post-exclusion), single acute dose (not chronic), and the preprint status (not yet peer-reviewed).